Analysts Set PolyPid Ltd. (NASDAQ:PYPD) PT at $12.25

Shares of PolyPid Ltd. (NASDAQ:PYPD) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $12.25.

Several analysts recently weighed in on the company. Roth Mkm cut their price target on PolyPid from $10.00 to $9.00 and set a “buy” rating on the stock in a research note on Thursday, November 13th. Citigroup reissued a “market outperform” rating on shares of PolyPid in a research note on Monday, December 1st. Weiss Ratings restated a “sell (d-)” rating on shares of PolyPid in a report on Monday, December 29th. Finally, Wall Street Zen upgraded shares of PolyPid from a “sell” rating to a “hold” rating in a research note on Sunday, November 16th.

Institutional Investors Weigh In On PolyPid

A number of institutional investors have recently made changes to their positions in PYPD. BNP Paribas Financial Markets increased its position in shares of PolyPid by 56.1% during the third quarter. BNP Paribas Financial Markets now owns 9,734 shares of the company’s stock valued at $32,000 after acquiring an additional 3,500 shares in the last quarter. Lumbard & Kellner LLC bought a new stake in shares of PolyPid in the 2nd quarter worth $135,000. Finally, AIGH Capital Management LLC increased its holdings in shares of PolyPid by 27.0% in the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock worth $4,215,000 after purchasing an additional 253,727 shares in the last quarter. Hedge funds and other institutional investors own 26.47% of the company’s stock.

PolyPid Trading Down 2.8%

Shares of PYPD stock opened at $4.58 on Wednesday. PolyPid has a 12 month low of $2.30 and a 12 month high of $5.05. The stock has a market cap of $72.81 million, a PE ratio of -1.54 and a beta of 1.51. The company’s fifty day moving average price is $4.23 and its 200-day moving average price is $3.75.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.54) by $0.17. On average, sell-side analysts forecast that PolyPid will post -1.79 earnings per share for the current fiscal year.

About PolyPid

PolyPid Ltd is a clinical‐stage biotechnology company focused on polymer‐based drug delivery technologies designed to enhance the performance of therapeutic agents at mucosal surfaces. Leveraging its proprietary Mucoadhesive & Mucus‐Penetrating (MMP) platform, PolyPid develops long‐acting formulations for ocular, oral and pulmonary indications. Its lead candidates include OncoTears and OralTear, therapies targeting dry eye and dry mouth conditions, respectively, as well as Paclical, a polymer‐formulated paclitaxel designed to improve tolerability and antitumor activity in oncology patients.

Founded in 2003 and headquartered in Jerusalem, Israel, PolyPid has assembled an international patent portfolio covering key markets in North America, Europe and Asia.